Abstract

  Hypertension is the most common regulating risk factor for cardiovascular disease (CVD) and death; the increased risk associated with blood pressure (BP) elevation can be greatly reduced by treatment with antihypertensive drugs that lower both BP and related target organ damage. Azelnidipine has also been confirmed to have cardio-protective, neuroprotective, and anti-atherosclerotic properties, and has also been found to prevent insulin resistance. Azelnidipine is dihydropyridine derivative with calcium antagonistic activity. Azelnidipine is inhibits trans membrane Ca+2 influx through the voltage dependent channels of smooth muscle in vascular walls. They enter the cells through cell membrane and is used for treatment of essential hypertension and angina pectoris. This review covers most recent analytical methods such as various spectroscopic methods, chromatographic methods and other methods for determination of Azelnidipine in various pharmaceutical dosage forms and biological matrix were reported.

Keywords: Azelnidipine; Analytical Methods; Antihypertensive Drug; Matrices; Estimation

References

1. Walker R and Whittlesea C. Clinical Pharmacy and Therapeutics; 5thEdn; Elsevier (2007): 295-307.
2. Shewale VU., et al. “Azelnidipine: A Review on Therapeutic Role in Hypertension”. Journal of Drug Delivery and Therapeutics 9 (2019): 1002-1005.
3. Chen B., et al. “Clinical use of azelnidipine in the treatment of hypertension in Chinese patients”. Therapeutics and Clinical Risk Management 11 (2015): 309-318.
4. Drug profile of “Azelnidipine” (2019). 
5. “Azelnidipine” (2019).
6. Tamargo J and Ruilope LM. “Investigational calcium channel blockers for the treatment of hypertension”. Expert Opinion on Investigational Drug (2016): 1-51.
7. Rele RV. “Spectrophotometric Estimation of Azelnidipine in Bulk drug and Pharmaceutical Dosage form by First Order Derivative and Area Under Curve Methods”. American Journal of PharmTech Research 4.2 (2014): 126-135.
8. Rele RV. “Spectrophotometric estimation of azelnidipine in bulk and pharmaceutical dosage form by second order derivative method”. Journal of Chemical and Pharmaceutical Research 6.8 (2014): 198-202.
9. Modi J., et al. “Stability Indicating Analytical Method Development and Validation for Estimation of Azelnidipine”. World Journal of Pharmaceutical Research (2016): 831-847.
10. Patel N and Patel JK. “Simultaneous Determination of Azelnidipine and Olmesartan medoxomil by First Derivative Spectrophotometric Method”. Scholar Research Library 4.4 (2012): 1080-1084.
11. Raskapur KD., et al. “UV-Spectrophotometric Method Development and Validation for Determinaton Of Azelnidipine In Pharmaceutical Dosage Form”. International Journal of Pharmacy and Pharmaceutical Sciences (2011): 238-240.
12. C Prabhakar., et al. “Method Development and Validation of Azelnidipine by RP-HPLC”. International Journal of Chem Tech Research 10.10 (2017): 418-423.
13. Amin AA., et al. “Simultaneous Determination of Azelnidipine and Olmesartan Medoxomil in Pharmaceutical Dosage Forms by UFLC Method”. Journal of Pharma SciTech (2016): 69-74.
14. Gore MG and Dabhade PS. “Rp-Hplc Method Development and Validation of Azelnidipine”. IJPSR (2016): 5111-5114.
15. Muralidharan S., et al. “Simple Validation of Azelnidipine By Rp-HPLC Method”. Rapports De Pharmacie 1.1 (2015): 43-45.
16. Ganduri RB., et al. “Stability Indicating Liquid Chromatographic Method for the Simultaneous Determination of Olmesartan Medoxomil and Azelnidipine in Combined Tablet Dosage Form”. IJPSR (2014): 275-282.
17. Patel NK and Patel JK. “Validated Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Azelnidipine and Olmesartan in Their Combined Dosage Form”. Scientia Pharmaceutica 82 (2014): 541-554.
18. Rane AS and Mahajan SK. “Validation and Forced Stability-Indicating Hptlc Method for Determination of Azelnidipine”. World Journal of Pharmaceutical Research (2016): 1053-1056.
19. Gao Y., et al. “A liquid chromatography- tandem mass spectrometric assay for the antihypertensive agent azelnidipine in human plasma with application to clinical pharmacokinetics studies”. Biomedical Chromatography 29 (2015): 970-974.
20. Suneetha G., et al. “Sensitive Analysis of Azelnidipine and Related Derivative in Human Plasma by Ultra-Performance Liquid Chromatography-Tandam Mass Spectrometry”. Asian Journal of Chemistry 25.18 (2013): 10319-10321.
21. Adepu R., et al. “A novel method for the simultaneous determination of Azelnidipine and Olmesartan in Human plasma by using liquid chromatography-electro spray Ionization tandem mass spectrometry and application to a pharmacokinetic study”. International Journal of Pharmaceutics 7.3 (2017): 111-124.

Citation

Citation: Kajal Patel. “In Depth Investigation of Analytical Methods for the Determination of Azelnidipine in Biological Fluid and Pharmaceutical Dosage Forms: A Review". Acta Scientific Biotechnology 1.4 (2020): 13-17.

Copyright

Copyright: © 2020 Kajal Patel. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.